Trial Profile

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Amino acids; Fludeoxyglucose F-18; Gallium 68-DOTATATE
Indications Paraganglioma; Phaeochromocytoma
Focus Therapeutic Use
Acronyms 177Lu-DOTATATE trial

Most Recent Events

13 Sep 2024 Planned number of patients changed from 90 to 130.
30 Jun 2022 Status changed from suspended to recruiting, according to a Novartis media release.
30 Jun 2022 According to a Novartis media release, company has remediated the issues that led to the temporary, voluntary suspension. These issues did not affect patient safety, and no risk to patients from the doses previously produced at these sites was identified. Company restarted screening and enrollment for clinical trials with Lutathera in the US and Canada.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com